Xeris Biopharma Holdings: Innovating Patient Care with Advanced Biopharmaceutical Therapies

Xeris Biopharma: Pioneering Innovative Therapies in Healthcare

Xeris Biopharma Holdings, Inc., based in Chicago, is at the forefront of transforming patient care through its innovative biopharmaceutical solutions. The company is dedicated to developing and commercializing therapies that address unmet medical needs, particularly for patients suffering from serious conditions. With a robust portfolio that includes three marketed products—Gvoke®, Keveyis®, and Recorlev®—Xeris actively contributes to improving patient outcomes in areas such as severe hypoglycemia, primary periodic paralysis, and endogenous Cushing’s syndrome. Each of these therapies reflects the company's commitment to enhance the quality of life for patients by leveraging advanced formulation technologies.

In preparation for its third quarter 2024 financial results, Xeris has scheduled a conference call for November 8, 2024, to provide insights into its financial and operational performance. This event underscores the company’s transparency and dedication to stakeholder engagement as it navigates the complexities of the biopharmaceutical landscape. With a clear focus on innovation, Xeris aims to keep investors and the public informed about its progress and strategic direction. The conference call, which is open for pre-registration, will include a discussion about the company's ongoing projects and future potential, further reinforcing its commitment to advancing healthcare solutions.

Moreover, Xeris is not resting on its current achievements; the company is actively expanding its pipeline with promising development and partnered programs. Utilizing its proprietary formulation technologies, XeriSol™ and XeriJect®, Xeris seeks to ensure the long-term viability of its products while addressing the diverse needs of patients. This strategic focus on research and development positions Xeris as a significant player in the biopharmaceutical industry, as it strives to deliver differentiated therapies that can significantly impact patient care and outcomes.

In addition to its upcoming financial results, Xeris Biopharma emphasizes its engagement with the public through various social media platforms, including X, LinkedIn, and Instagram. This digital presence allows the company to communicate its mission and innovations to a broader audience. As Xeris continues to push the boundaries of biopharmaceutical advancements, its unwavering commitment to patient care remains a core element of its strategy, ensuring that it remains a key contributor to the evolving landscape of healthcare.